Reasons to Buy

Rigel is a biotechnology company selling therapies for hematologic disorders and cancer, including TAVALISSE, REZLIDHIA and GAVRETO. In Q2 2026, net product sales increased 14% year over year, led by TAVALISSE and REZLIDHIA, while Rigel remained profitable and raised full-year guidance. Newly licensed VEPPANU, an FDA-approved PROTAC for ESR1 mutated metastatic breast cancer, adds growth potential.

Potential Risks

Execution risk is rising. Rigel paid $70 million upfront for VEPPANU, lowering cash, while operating costs increased. GAVRETO sales declined, and uptake, reimbursement and competition in oncology markets can be uneven.

Forecast

A Zacks Rank #3 (Hold), with a Value Score of A, Growth Score of D and Momentum Score of D, suggests a neutral outlook despite attractive valuation. The chart shows 2026 through 2028 EPS estimates retreating from late 2025 peaks, while recent surprises have shifted toward misses. Price volatility remains high, so stronger VEPPANU uptake or renewed estimate revisions would improve the setup.